Keros Therapeutics reports Q4 2023 net loss of $40.2M, cash $331.1M; extends runway into 2027

Keros Therapeutics, Inc.

2023-FY EPS reported -$5.20 revenue$151,000

Net loss of $40.2M in Q4 2023 ($153.0M for FY) vs $29.7M and $104.7M in prior year periods.
Revenue of $0.2M in 2023 from license agreement with Hansoh; no revenue in 2022.
R&D expenses rose to $37.5M in Q4 (FY $135.3M) driven by Phase 2 trials of KER-050 and KER-012.
Cash and equivalents $331.1M at Dec 31, 2023; January 2024 public offering of 4.025M shares at $40/sh adds net proceeds, funding into 2027.
Anticipated milestones: Phase 3 trial design for KER-050 in MDS in H1 2024; data readouts throughout 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.2 million for the year ended December 31, 2023, net income a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $0.2 million for the year ended December 31, 2023
Net income: a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023
Result: reported results

Exact text from the filing

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.